Shopping Cart
Remove All
Your shopping cart is currently empty
Buloxibutid (AT2 receptor agonist C21) is a novel and selective small molecule angiotensin II AT2 receptor agonist, exhibiting Ki values of 0.4 nM and 10 μM for AT2 and AT1 receptors, respectively.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $42 | In Stock | In Stock | |
| 5 mg | $98 | In Stock | In Stock | |
| 10 mg | $156 | In Stock | In Stock | |
| 25 mg | $289 | In Stock | In Stock | |
| 50 mg | $455 | In Stock | In Stock | |
| 100 mg | $787 | - | In Stock | |
| 500 mg | $1,580 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $98 | In Stock | In Stock |
| Description | Buloxibutid (AT2 receptor agonist C21) is a novel and selective small molecule angiotensin II AT2 receptor agonist, exhibiting Ki values of 0.4 nM and 10 μM for AT2 and AT1 receptors, respectively. |
| Targets&IC50 | AT1:>10 μM(ki), AT2:0.4 nM(ki) |
| In vivo | Buloxibutid, with an oral bioavailability of 20-30% and a 4-hour half-life in rats, induces neurite cell outgrowth, stimulates p42/p44mapk, enhances in vivo duodenal alkaline secretion in Sprague-Dawley rats, and lowers mean arterial blood pressure in anesthetized, spontaneously hypertensive rats. [1] |
| Synonyms | AT2 receptor agonist C21 |
| Molecular Weight | 475.62 |
| Formula | C23H29N3O4S2 |
| Cas No. | 477775-14-7 |
| Smiles | CCCCOC(=O)NS(=O)(=O)c1sc(CC(C)C)cc1-c1ccc(Cn2ccnc2)cc1 |
| Relative Density. | 1.27 g/cm3 (Predicted) |
| Color | Yellow |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 22.5 mg/mL (47.31 mM), Sonication is recommended. | |||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 2 mg/mL (4.21 mM), Sonication is recommeded. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.